Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Expression of NIS Protein and mRNA in Thyroid Tumors

This study has been completed.
Sponsor:
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Information provided by:
University of Sao Paulo
ClinicalTrials.gov Identifier:
NCT00459498
First received: April 10, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
  Purpose

The uptake of iodide by thyroid cells requires the expression of sodium iodide symporter (NIS). Thyroid benign and malignant tumors have low iodide uptake activity. Previous studies of NIS expression with RT-PCR and immunohistochemistry showed divergent data. NIS protein was overexpressed in thyroid cancer. The aim of this study was to investigate the NIS transcript levels and its presence and localization in 30 samples of thyroid tumors (14 benign and 16 malignant) and in their surrounding non-tumoral tissues (NT), by real time RT-PCR and immunohistochemistry, respectively. Our results revealed lower gene expression in 78.6% of the benign tumors and 100% of the carcinomas when compared with the NT samples, using GHPDH as a housekeeping gene. Immunohistochemical staining revealed presence of NIS protein in 100% of the non-tumoral samples, 100% of the benign tumors and 93.75% of the malignant tumors. NIS protein was identified at basolateral membrane in 23.3% of non-tumoral samples, 14.3% of benign and 12.5% of malignant tumors. Stronger cytoplasmatic immunostaining of NIS protein was detected in 64.3% of benign tumors and in 87.5% of malignant tumors when compared to NT. Association between low gene expression and strong cytoplasmatic immunostaining was found in 50% of benign tumors and 87.5% of malignant tumors. We concluded that the reduced NIS gene expression in thyroid tumors associated with strong intracytoplasmatic staining may be due to its incapacity to migrate to cellular membrane.


Condition
Tumors

Study Type: Observational
Study Design: Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors

Resource links provided by NLM:


Further study details as provided by University of Sao Paulo:

Estimated Enrollment: 30
Study Start Date: April 2002
Study Completion Date: October 2006
Detailed Description:

The aim of this study was to quantify NIS transcript levels by real time PCR and to determine the presence and cellular localization of NIS protein by immunohistochemistry, in benign and malignant thyroid tumor cells and to compare with their paired surrounding non-tumoral cell. NIS expression was also compared to that of the TSHR

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PAtients with thyroid tumors undergoing surgery for total or partial thyroidectomy

Exclusion Criteria:

  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00459498

Sponsors and Collaborators
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo
Investigators
Principal Investigator: Ana K Sodré University of São Paulo
Study Director: Rosalinda Y Camargo University of São Paulo
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00459498     History of Changes
Other Study ID Numbers: PRN736/02
Study First Received: April 10, 2007
Last Updated: April 10, 2007
Health Authority: Brazil: Ministry of Health

Keywords provided by University of Sao Paulo:
NIS
thyroid adenoma
thyroid cancer
Iodine uptake
expression

Additional relevant MeSH terms:
Thyroid Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Head and Neck Neoplasms
Neoplasms
Neoplasms by Site
Thyroid Diseases

ClinicalTrials.gov processed this record on November 25, 2014